Pub Date : 2025-03-05DOI: 10.1021/acs.jmedchem.5c00539
Changhong Wei, Yun Liu, Zhiming Yan, Jing Han, Neng Jiang
Dual modulation of FXR and HSD17B13 presents a promising strategy for treating metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH). Compound 6, a groundbreaking dual modulator of FXR and HSD17B13, validates the concept of significantly enhancing liver function, reducing inflammation and fibrosis across various MAFLD models.
{"title":"Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH","authors":"Changhong Wei, Yun Liu, Zhiming Yan, Jing Han, Neng Jiang","doi":"10.1021/acs.jmedchem.5c00539","DOIUrl":"https://doi.org/10.1021/acs.jmedchem.5c00539","url":null,"abstract":"Dual modulation of FXR and HSD17B13 presents a promising strategy for treating metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH). Compound <b>6</b>, a groundbreaking dual modulator of FXR and HSD17B13, validates the concept of significantly enhancing liver function, reducing inflammation and fibrosis across various MAFLD models.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"53 1","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143561254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-04DOI: 10.1021/acs.jmedchem.4c02759
Dong-Ming Shen, Kate F. Byth, Damien Bertheloot, Simona Braams, Sarah Bradley, Dennis Dean, Carien Dekker, Ayman F. El-Kattan, Luigi Franchi, Gary D. Glick, Shomir Ghosh, Alexandra Hinniger, Jason D. Katz, Ana Kitanovic, Xiaokang Lu, Edward J. Olhava, Anthony W. Opipari, Brian Sanchez, H. Martin Seidel, James Stunden, Andrea Stutz, Alissa Telling, Shankar Venkatraman, David G. Winkler, William R. Roush
The discovery of DFV890 ((R)-1), a potent and selective NLRP3 antagonist, is described. Replacement of the sulfonyl urea core from the first-generation NLRP3 antagonist CRID3 with a sulfonimidamide core afforded a novel and potent series of NLRP3 antagonists. The (R)-enantiomers of the sulfonimidamide series were found to be consistently more potent than structurally related sulfonyl ureas. Replacement of the furan unit of CRID3 with a 5-substituted thiazole unit led to DFV890 ((R)-1), which potently inhibited IL-1β production in THP-1 cells and in primary human cells, blocked multiple downstream effectors of NLRP3 activation, and substantially improved PK properties and significantly lowered the predicted human dose compared to that for CRID3. DFV890 ((R)-1) was also effective in an air pouch model of gout.
{"title":"Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor","authors":"Dong-Ming Shen, Kate F. Byth, Damien Bertheloot, Simona Braams, Sarah Bradley, Dennis Dean, Carien Dekker, Ayman F. El-Kattan, Luigi Franchi, Gary D. Glick, Shomir Ghosh, Alexandra Hinniger, Jason D. Katz, Ana Kitanovic, Xiaokang Lu, Edward J. Olhava, Anthony W. Opipari, Brian Sanchez, H. Martin Seidel, James Stunden, Andrea Stutz, Alissa Telling, Shankar Venkatraman, David G. Winkler, William R. Roush","doi":"10.1021/acs.jmedchem.4c02759","DOIUrl":"https://doi.org/10.1021/acs.jmedchem.4c02759","url":null,"abstract":"The discovery of DFV890 ((<i>R</i>)-<b>1</b>), a potent and selective NLRP3 antagonist, is described. Replacement of the sulfonyl urea core from the first-generation NLRP3 antagonist CRID3 with a sulfonimidamide core afforded a novel and potent series of NLRP3 antagonists. The <i>(R)-</i>enantiomers of the sulfonimidamide series were found to be consistently more potent than structurally related sulfonyl ureas. Replacement of the furan unit of CRID3 with a 5-substituted thiazole unit led to DFV890 ((<i>R</i>)-<b>1</b>), which potently inhibited IL-1β production in THP-1 cells and in primary human cells, blocked multiple downstream effectors of NLRP3 activation, and substantially improved PK properties and significantly lowered the predicted human dose compared to that for CRID3. DFV890 ((<i>R</i>)-<b>1</b>) was also effective in an air pouch model of gout.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"30 1","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143545873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-04DOI: 10.1021/acs.jmedchem.4c03146
Kaiyue Liu, Yunyun Ji, Yiming Xie, Chengyan Wang, Jie Zhou, Ziyi Wei, Xiaoyu Wang, Xiaotong Zheng, Yao Cen, Fan Zhang, Bailing Xu
TREK-1 regulates neuronal excitability and neuronal cell apoptosis, and inhibition of TREK-1 is a potential strategy to prevent cell death and achieve neuroprotection in an ischemic stroke. In this work, a series of novel isobenzofuran-1(3H)-one derivatives were designed and synthesized as TREK-1 inhibitors, and extensive structure–activity relationships led to the discovery of potent and selective TREK-1 inhibitors having IC50 values of a low micromolar level. Among them, Cpd8l potently and selectively inhibited TREK-1 (IC50 = 0.81 μM, selectivity >30 fold over other K+, Na+, and TRP channels). Cpd8l remarkably reduced the neuron death in the OGD/R-induced cortical neuronal injury model, while adenovirus silencing TREK-1 reduced its neuroprotective effect. Furthermore, Cpd8l could effectively ameliorate brain injury in MCAO/R model mice. Collectively, this work demonstrates that Cpd8l may serve as a novel lead compound to develop a highly potent and selective TREK-1 inhibitor for ischemic stroke treatment.
{"title":"Discovery of Isobenzofuran-1(3H)-one Derivatives as Selective TREK-1 Inhibitors with In Vitro and In Vivo Neuroprotective Effects","authors":"Kaiyue Liu, Yunyun Ji, Yiming Xie, Chengyan Wang, Jie Zhou, Ziyi Wei, Xiaoyu Wang, Xiaotong Zheng, Yao Cen, Fan Zhang, Bailing Xu","doi":"10.1021/acs.jmedchem.4c03146","DOIUrl":"https://doi.org/10.1021/acs.jmedchem.4c03146","url":null,"abstract":"TREK-1 regulates neuronal excitability and neuronal cell apoptosis, and inhibition of TREK-1 is a potential strategy to prevent cell death and achieve neuroprotection in an ischemic stroke. In this work, a series of novel isobenzofuran-1(3<i>H</i>)-one derivatives were designed and synthesized as TREK-1 inhibitors, and extensive structure–activity relationships led to the discovery of potent and selective TREK-1 inhibitors having IC<sub>50</sub> values of a low micromolar level. Among them, <b>Cpd8l</b> potently and selectively inhibited TREK-1 (IC<sub>50</sub> = 0.81 μM, selectivity >30 fold over other K<sup>+</sup>, Na<sup>+</sup>, and TRP channels). <b>Cpd8l</b> remarkably reduced the neuron death in the OGD/R-induced cortical neuronal injury model, while adenovirus silencing TREK-1 reduced its neuroprotective effect. Furthermore, <b>Cpd8l</b> could effectively ameliorate brain injury in MCAO/R model mice. Collectively, this work demonstrates that <b>Cpd8l</b> may serve as a novel lead compound to develop a highly potent and selective TREK-1 inhibitor for ischemic stroke treatment.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"67 1","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143545887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-04DOI: 10.1021/acs.jmedchem.5c00258
Zhaomin Xia, Qiumei Zhu, Yi Shan, Jiayu Lu, Meidi An, Xiaoxue Mo, Siqi Wang, Wen Yang, Hua Qian, Huaizhen He, Cheng Wang
Mas-related G protein-coupled receptor X2 (MrgX2) plays a key role in pseudoallergy reactions; thus, it is of great significance to screen compounds with antipseudoallergy activity via MrgX2. Cell membrane chromatography (CMC) demonstrates great potential in drug screening, but it requires further optimization to improve its specificity and stability. In this study, a new CMC system incorporating His-tag-oriented immobilized proteins was constructed to screen MrgX2 antagonists. Single His-tag-fused MrgX2 was extracted intactly and covalently bond to divinyl sulfone-modified amino silica gel to obtain bioaffinity composites. The characterized composites were utilized to establish a MrgX2-His-tag@VS/CMC system to screen MrgX2 antagonists. Compound Z-3578 was screened from a G protein-coupled receptor compound library of 3010 compounds and revealed its efficient antipseudoallergy activity in vitro and in vivo via MrgX2. In conclusion, the new oriented-immobilized CMC system will provide an efficient analytical tool for screening active precursors.
{"title":"MrgX2-Targeting Ligand Screen for Antipseudoallergic Agents by Immobilized His-Tag-Fused Protein Technology","authors":"Zhaomin Xia, Qiumei Zhu, Yi Shan, Jiayu Lu, Meidi An, Xiaoxue Mo, Siqi Wang, Wen Yang, Hua Qian, Huaizhen He, Cheng Wang","doi":"10.1021/acs.jmedchem.5c00258","DOIUrl":"https://doi.org/10.1021/acs.jmedchem.5c00258","url":null,"abstract":"Mas-related G protein-coupled receptor X2 (MrgX2) plays a key role in pseudoallergy reactions; thus, it is of great significance to screen compounds with antipseudoallergy activity via MrgX2. Cell membrane chromatography (CMC) demonstrates great potential in drug screening, but it requires further optimization to improve its specificity and stability. In this study, a new CMC system incorporating His-tag-oriented immobilized proteins was constructed to screen MrgX2 antagonists. Single His-tag-fused MrgX2 was extracted intactly and covalently bond to divinyl sulfone-modified amino silica gel to obtain bioaffinity composites. The characterized composites were utilized to establish a MrgX2-His-tag@VS/CMC system to screen MrgX2 antagonists. Compound Z-3578 was screened from a G protein-coupled receptor compound library of 3010 compounds and revealed its efficient antipseudoallergy activity in vitro and in vivo via MrgX2. In conclusion, the new oriented-immobilized CMC system will provide an efficient analytical tool for screening active precursors.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"35 1","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143545876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-04DOI: 10.1021/acs.jmedchem.4c03067
Kevin M. Cottrell, Kimberly J. Briggs, Alice Tsai, Matthew R. Tonini, Douglas A. Whittington, Shanzhong Gong, Colin Liang, Patrick McCarren, Minjie Zhang, Wenhai Zhang, Alan Huang, John P. Maxwell
The gene encoding for MTAP is one of the most commonly deleted genes in cancer, occurring in approximately 10–15% of all human cancer. We have previously described the discovery of TNG908, a brain-penetrant clinical-stage compound that selectively targets MTAP-deleted cancer cells by binding to and inhibiting PRMT5 cooperatively with MTA, which is present in elevated concentrations in MTAP-deleted cells. Herein we describe the discovery of TNG462, a more potent and selective MTA-cooperative PRMT5 inhibitor with improved DMPK properties that is selective for MTAP-deleted cancers and is currently in Phase I/II clinical trials.
{"title":"Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion","authors":"Kevin M. Cottrell, Kimberly J. Briggs, Alice Tsai, Matthew R. Tonini, Douglas A. Whittington, Shanzhong Gong, Colin Liang, Patrick McCarren, Minjie Zhang, Wenhai Zhang, Alan Huang, John P. Maxwell","doi":"10.1021/acs.jmedchem.4c03067","DOIUrl":"https://doi.org/10.1021/acs.jmedchem.4c03067","url":null,"abstract":"The gene encoding for MTAP is one of the most commonly deleted genes in cancer, occurring in approximately 10–15% of all human cancer. We have previously described the discovery of TNG908, a brain-penetrant clinical-stage compound that selectively targets <i>MTAP</i>-deleted cancer cells by binding to and inhibiting PRMT5 cooperatively with MTA, which is present in elevated concentrations in <i>MTAP</i>-deleted cells. Herein we describe the discovery of TNG462, a more potent and selective MTA-cooperative PRMT5 inhibitor with improved DMPK properties that is selective for <i>MTAP</i>-deleted cancers and is currently in Phase I/II clinical trials.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"9 1","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-04DOI: 10.1021/acs.jmedchem.4c03158
Purav P. Vagadia, Javier Izquierdo-Ferrer, Candice Mazewski, Gavin Blyth, Elspeth M. Beauchamp, Matthew R. Clutter, Charlotte L. Stern, Rama K. Mishra, Dominik Nahotko, Sara Small, Frank Eckerdt, Leonidas C. Platanias, Gary E. Schiltz
MNK activity is regulated by the p38 and Erk MAPK pathways. Phosphorylation of MNK leads to its activation and binding to the eIF4G/eIF4E complex. MNK then phosphorylates eIF4E at Ser209, whose activation is associated with oncogene translation, leading to tumorigenesis. Given this important role for eIF4E in tumorigenesis, MNK inhibition with novel small molecule inhibitors could be a promising strategy to combat AML, which continues to be an area of unmet medical need. Here, we report the medicinal optimization of a series of novel inhibitors and their evaluation of their effects on eIF4E and leukemia cell viability. We discovered a class of ether-containing compounds with a high MNK1/2 selectivity. These MNK inhibitors show good potency in reducing cell viability and colony formation and have desirable pharmacokinetic properties. X-ray cocrystallization was accomplished to confirm the binding mode of our inhibitors and aid in future optimization.
{"title":"Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia","authors":"Purav P. Vagadia, Javier Izquierdo-Ferrer, Candice Mazewski, Gavin Blyth, Elspeth M. Beauchamp, Matthew R. Clutter, Charlotte L. Stern, Rama K. Mishra, Dominik Nahotko, Sara Small, Frank Eckerdt, Leonidas C. Platanias, Gary E. Schiltz","doi":"10.1021/acs.jmedchem.4c03158","DOIUrl":"https://doi.org/10.1021/acs.jmedchem.4c03158","url":null,"abstract":"MNK activity is regulated by the p38 and Erk MAPK pathways. Phosphorylation of MNK leads to its activation and binding to the eIF4G/eIF4E complex. MNK then phosphorylates eIF4E at Ser209, whose activation is associated with oncogene translation, leading to tumorigenesis. Given this important role for eIF4E in tumorigenesis, MNK inhibition with novel small molecule inhibitors could be a promising strategy to combat AML, which continues to be an area of unmet medical need. Here, we report the medicinal optimization of a series of novel inhibitors and their evaluation of their effects on eIF4E and leukemia cell viability. We discovered a class of ether-containing compounds with a high MNK1/2 selectivity. These MNK inhibitors show good potency in reducing cell viability and colony formation and have desirable pharmacokinetic properties. X-ray cocrystallization was accomplished to confirm the binding mode of our inhibitors and aid in future optimization.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"211 1","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Src homology-2-containing protein tyrosine phosphatase (PTP) 2 (SHP2) is a pivotal PTP that modulates key cellular processes including proliferation, differentiation, and migration. Its overexpression is implicated in the pathogenesis of various malignancies, highlighting the need for effective SHP2 inhibitors. Herein, we report the design and synthesis of a novel series of thiazolo[5,4-b]pyridine and imidazo[1,2-c]pyrimidine derivatives as SHP2 allosteric inhibitors identified through active fragment splicing. The synthesized compounds exhibited potent SHP2 inhibition, with IC50 values ranging from 9.0 to 34.5 nM. Notably, compound B8 demonstrated superior potency, with an IC50 of 0.04 μM for p-ERK modulation. Compound B8 also displayed favorable drug-like properties and significant antitumor activity in a KYSE520 xenograft mouse model, underscoring its potential as a lead candidate for further development. Our findings provide a foundation for the advancement of SHP2-targeted therapeutics.
{"title":"Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects","authors":"Cheng Shi, Yanping Zhao, Han Huang, Jiaxu Zhou, Dehua Lu, Yanming Chen, Weiping Lyu, Zhenming Liu, Hongjun Wang, Liangren Zhang","doi":"10.1021/acs.jmedchem.4c02100","DOIUrl":"https://doi.org/10.1021/acs.jmedchem.4c02100","url":null,"abstract":"Src homology-2-containing protein tyrosine phosphatase (PTP) 2 (SHP2) is a pivotal PTP that modulates key cellular processes including proliferation, differentiation, and migration. Its overexpression is implicated in the pathogenesis of various malignancies, highlighting the need for effective SHP2 inhibitors. Herein, we report the design and synthesis of a novel series of thiazolo[5,4-<i>b</i>]pyridine and imidazo[1,2-<i>c</i>]pyrimidine derivatives as SHP2 allosteric inhibitors identified through active fragment splicing. The synthesized compounds exhibited potent SHP2 inhibition, with IC<sub>50</sub> values ranging from 9.0 to 34.5 nM. Notably, compound <b>B8</b> demonstrated superior potency, with an IC<sub>50</sub> of 0.04 μM for p-ERK modulation. Compound <b>B8</b> also displayed favorable drug-like properties and significant antitumor activity in a KYSE520 xenograft mouse model, underscoring its potential as a lead candidate for further development. Our findings provide a foundation for the advancement of SHP2-targeted therapeutics.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"46 1","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-04DOI: 10.1021/acs.jmedchem.4c03120
Chad R. Schultz, Bilal Aleiwi, X. Edward Zhou, Kelly Suino-Powell, Karsten Melcher, Nuno M. S. Almeida, Angela K. Wilson, Edmund L. Ellsworth, André S. Bachmann
We here describe the design, synthesis, and biological activity of novel ornithine decarboxylase (ODC) inhibitors that show significantly higher potency in vitro than α-difluoromethylornithine (DFMO), a U.S. Food and Drug Administration (FDA) approved drug. We report two X-ray structures of ODC complexed with new ODC inhibitors, computational docking, molecular dynamics, and binding free energy calculations to validate the experimental models. The X-ray structures reveal that covalent adducts with pyridoxal phosphate (PLP) are formed in the active site of the human ODC enzyme, as verified by their preparation and enzymatic testing. Finally, we verified that the cellular activity of endogenous ODC was inhibited, and polyamine levels were reduced. Given that ODC is a clinically validated target, combined with the fact that DFMO is currently the only ODC inhibitor in clinical use for several indications, the further development of more potent ODC inhibitors with superior activity and physical properties is warranted.
{"title":"Design, Synthesis, and Biological Activity of Novel Ornithine Decarboxylase (ODC) Inhibitors","authors":"Chad R. Schultz, Bilal Aleiwi, X. Edward Zhou, Kelly Suino-Powell, Karsten Melcher, Nuno M. S. Almeida, Angela K. Wilson, Edmund L. Ellsworth, André S. Bachmann","doi":"10.1021/acs.jmedchem.4c03120","DOIUrl":"https://doi.org/10.1021/acs.jmedchem.4c03120","url":null,"abstract":"We here describe the design, synthesis, and biological activity of novel ornithine decarboxylase (ODC) inhibitors that show significantly higher potency <i>in vitro</i> than α-difluoromethylornithine (DFMO), a U.S. Food and Drug Administration (FDA) approved drug. We report two X-ray structures of ODC complexed with new ODC inhibitors, computational docking, molecular dynamics, and binding free energy calculations to validate the experimental models. The X-ray structures reveal that covalent adducts with pyridoxal phosphate (PLP) are formed in the active site of the human ODC enzyme, as verified by their preparation and enzymatic testing. Finally, we verified that the cellular activity of endogenous ODC was inhibited, and polyamine levels were reduced. Given that ODC is a clinically validated target, combined with the fact that DFMO is currently the only ODC inhibitor in clinical use for several indications, the further development of more potent ODC inhibitors with superior activity and physical properties is warranted.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"41 1","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-04DOI: 10.1021/acs.jmedchem.4c03156
Pankaj Sharma, Quan Jiang, Shao-Gang Li, Elissa Ocke, Kholiswa Tsotetsi, Paridhi Sukheja, Parul Singh, Shraddha Suryavanshi, Ethan Morrison, Srinivas Thadkapally, Riccardo Russo, Suyapa Penalva-Lopez, Julianna Cangialosi, Vijeta Sharma, Kyla Johnson, Jansy P. Sarathy, Andrew M. Nelson, Steven Park, Matthew D. Zimmerman, David Alland, Pradeep Kumar, Joel S. Freundlich
A dire need exists for novel drugs to treat Mycobacterium tuberculosis infection. In an effort to build on our early efforts targeting the MenG enzyme within the menaquinone biosynthetic pathway, we have pursued the optimization of diaryl amide JSF-2911 to address its poor metabolic stability and modest in vitro potency. A hit evolution campaign focused on modification of the amine substructure within this hit compound, resulting in a range of analogues that have been profiled extensively. Among these derivatives, JSF-4536 and JSF-4898 demonstrated significantly improved biological profiles, notably offering submicromolar MIC values versus M. tuberculosis and promising values characterizing the mouse liver microsome stability, aqueous solubility, and mouse pharmacokinetic profile. JSF-4898 enhanced the efficacy of rifampicin in a subacute model of M. tuberculosis infection in mice. The findings suggest a rationale for the further optimization of MenG inhibitors to provide a novel therapeutic strategy to address M. tuberculosis infection.
{"title":"Evolution of Small Molecule Inhibitors of Mycobacterium tuberculosis Menaquinone Biosynthesis","authors":"Pankaj Sharma, Quan Jiang, Shao-Gang Li, Elissa Ocke, Kholiswa Tsotetsi, Paridhi Sukheja, Parul Singh, Shraddha Suryavanshi, Ethan Morrison, Srinivas Thadkapally, Riccardo Russo, Suyapa Penalva-Lopez, Julianna Cangialosi, Vijeta Sharma, Kyla Johnson, Jansy P. Sarathy, Andrew M. Nelson, Steven Park, Matthew D. Zimmerman, David Alland, Pradeep Kumar, Joel S. Freundlich","doi":"10.1021/acs.jmedchem.4c03156","DOIUrl":"https://doi.org/10.1021/acs.jmedchem.4c03156","url":null,"abstract":"A dire need exists for novel drugs to treat <i>Mycobacterium tuberculosis</i> infection. In an effort to build on our early efforts targeting the MenG enzyme within the menaquinone biosynthetic pathway, we have pursued the optimization of diaryl amide JSF-2911 to address its poor metabolic stability and modest <i>in vitro</i> potency. A hit evolution campaign focused on modification of the amine substructure within this hit compound, resulting in a range of analogues that have been profiled extensively. Among these derivatives, JSF-4536 and JSF-4898 demonstrated significantly improved biological profiles, notably offering submicromolar MIC values versus <i>M. tuberculosis</i> and promising values characterizing the mouse liver microsome stability, aqueous solubility, and mouse pharmacokinetic profile. JSF-4898 enhanced the efficacy of rifampicin in a subacute model of <i>M. tuberculosis</i> infection in mice. The findings suggest a rationale for the further optimization of MenG inhibitors to provide a novel therapeutic strategy to address <i>M. tuberculosis</i> infection.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"67 1","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ATR is one of the key DNA damage response (DDR) regulatory factors to maintain genome stability. ATR inhibition induces DNA damage accumulation and apoptosis in DDR kinase mutation or deficiency cancer cells through synthetic lethality, making it a promising target for treatment of cancers with DDR defects. Herein, we describe the discovery and preclinical evaluation of YY2201, a highly potent and selective novel ATR inhibitor, with favorable ADME, safety pharmacology, and pharmacokinetics profiles. YY2201 efficiently inhibits tumor progression in broad-spectrum cancer types, both in vitro and in vivo. YY2201 shows superior in vivo anticancer efficacy and a better therapeutic index compared to AZD6738 in a lung cancer xenograft model. YY2201 also exhibits potent cancer suppression effects in combination with chemotherapy in vivo. Currently, the investigational new drug application of YY2201 has been approved by the FDA for further clinical investigation.
{"title":"Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor","authors":"Meng Wu, Xiaofang Chen, Haoran Wang, Chang Li, Wenjin Liu, Xiao Zheng, Jingxin Yang, Xin Ye, Yali Weng, Tianyun Fan, Huimin Hou","doi":"10.1021/acs.jmedchem.4c02380","DOIUrl":"https://doi.org/10.1021/acs.jmedchem.4c02380","url":null,"abstract":"ATR is one of the key DNA damage response (DDR) regulatory factors to maintain genome stability. ATR inhibition induces DNA damage accumulation and apoptosis in DDR kinase mutation or deficiency cancer cells through synthetic lethality, making it a promising target for treatment of cancers with DDR defects. Herein, we describe the discovery and preclinical evaluation of <b>YY2201</b>, a highly potent and selective novel ATR inhibitor, with favorable ADME, safety pharmacology, and pharmacokinetics profiles. <b>YY2201</b> efficiently inhibits tumor progression in broad-spectrum cancer types, both <i>in vitro</i> and <i>in vivo</i>. <b>YY2201</b> shows superior <i>in vivo</i> anticancer efficacy and a better therapeutic index compared to AZD6738 in a lung cancer xenograft model. <b>YY2201</b> also exhibits potent cancer suppression effects in combination with chemotherapy <i>in vivo</i>. Currently, the investigational new drug application of <b>YY2201</b> has been approved by the FDA for further clinical investigation.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"40 1","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：